Pharmaceuticals, Biotechnology and Life Sciences
Boehringer Ingelheim’s nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD), has been put to the fast…
Boehringer Ingelheim has appointed new CEO Wednesday, who will replace Paul Fonteyne, as he will retire after 15 years, on December…
Boehringer Ingelheim Pharmaceuticals has gotten an approval from the FDA, for a broadened indication of its afatinib for patients with…
Boehringer Ingelheim today announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million.
Boehringer Ingelheim today announced a collaborative agreement with Roche, focusing on the discovery and development of orally available novel Locked…
Hikma Pharmaceuticals has acquired six products from Boehringer Ingelheim GmbH (Boehringer Ingelheim).
Boehringer Ingelheim has reported that final results from RE-VERSE AD study showed that idarucizumab, marketed in the U.S. as Praxbind, was able to immediately reverse the anticoagulant effect of Pradaxa (dabigatran etexilate mesylate) in patients in emergency situations.
Boehringer Ingelheim (BI) and Eli Lilly are preparing to investigate Jardiance (empagliflozin) tablets for the treatment of people with chronic kidney disease.
Boehringer Ingelheim has reported new analyses that provide further evidence that adding SPIRIVA RESPIMAT improved breathing across diverse patient populations who experience uncontrolled asthma symptoms despite the use of another daily maintenance therapy in the Phase III clinical development program.
Verona Pharma has made an important step in the phase two clinical trial for its candidate RPL554, used for chronic obstructive pulmonary disease (COPD). Namely, the first patient has been dosed testing RPL544 as an add-on therapy to tiotropium, Spiriva.